DE602007012743D1 - USE OF AN ANTIBODY AGAINST CD151 IN THE TREATMENT OF PRIMARY CANCER - Google Patents

USE OF AN ANTIBODY AGAINST CD151 IN THE TREATMENT OF PRIMARY CANCER

Info

Publication number
DE602007012743D1
DE602007012743D1 DE602007012743T DE602007012743T DE602007012743D1 DE 602007012743 D1 DE602007012743 D1 DE 602007012743D1 DE 602007012743 T DE602007012743 T DE 602007012743T DE 602007012743 T DE602007012743 T DE 602007012743T DE 602007012743 D1 DE602007012743 D1 DE 602007012743D1
Authority
DE
Germany
Prior art keywords
treatment
protein
antibody against
primary cancer
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007012743T
Other languages
German (de)
Inventor
Jean-Francois Haeuw
Liliane Goetsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37866318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602007012743(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of DE602007012743D1 publication Critical patent/DE602007012743D1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Use of an antibody, or one of its functional fragments capable of binding to cluster of differentiation (CD)-151 protein and inhibiting the tumor growth for the preparation of a medicament for the treatment of cancer, is claimed. An independent claim is included for a composition for treating cancer, comprising the anti-CD151 antibody as active ingredient, which binds to the protein CD151 and/or to inhibit its metastasis promoting activity. ACTIVITY : Cytostatic. MECHANISM OF ACTION : CD151 protein binder.
DE602007012743T 2006-10-18 2007-10-15 USE OF AN ANTIBODY AGAINST CD151 IN THE TREATMENT OF PRIMARY CANCER Active DE602007012743D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609135A FR2907341B1 (en) 2006-10-18 2006-10-18 USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER
PCT/FR2007/001688 WO2008049990A2 (en) 2006-10-18 2007-10-15 Use of an anti-cd151 antibody in the treatment of cancer

Publications (1)

Publication Number Publication Date
DE602007012743D1 true DE602007012743D1 (en) 2011-04-07

Family

ID=37866318

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007012743T Active DE602007012743D1 (en) 2006-10-18 2007-10-15 USE OF AN ANTIBODY AGAINST CD151 IN THE TREATMENT OF PRIMARY CANCER

Country Status (28)

Country Link
US (2) US8178096B2 (en)
EP (1) EP2079482B1 (en)
JP (2) JP5757646B2 (en)
KR (1) KR101521863B1 (en)
CN (1) CN101528256B (en)
AT (1) ATE499387T1 (en)
AU (1) AU2007310763B2 (en)
BR (1) BRPI0717455A2 (en)
CA (1) CA2665912C (en)
DE (1) DE602007012743D1 (en)
DK (1) DK2079482T3 (en)
ES (1) ES2361696T3 (en)
FR (1) FR2907341B1 (en)
HK (1) HK1132904A1 (en)
HR (1) HRP20110374T1 (en)
IL (1) IL198043A (en)
MA (1) MA30777B1 (en)
MX (1) MX2009003039A (en)
NO (1) NO20091919L (en)
NZ (1) NZ575781A (en)
PL (1) PL2079482T3 (en)
PT (1) PT2079482E (en)
RS (1) RS51729B (en)
RU (1) RU2464041C2 (en)
SI (1) SI2079482T1 (en)
TN (1) TN2009000144A1 (en)
UA (1) UA99601C2 (en)
WO (1) WO2008049990A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873699B1 (en) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF
FR2907341B1 (en) * 2006-10-18 2012-08-17 Pf Medicament USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER
FR2929946B1 (en) * 2008-04-11 2010-05-28 Pf Medicament NOVEL ANTI-CD151 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
CN102605057A (en) * 2012-02-28 2012-07-25 芮屈生物技术（上海）有限公司 In-situ hybridization assay kit for mRNA level of premalignant CD151 as well as assay method and application
WO2016081455A1 (en) * 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody
RU2746314C2 (en) 2016-06-09 2021-04-12 Пеликан Терапьютикс, Инк. Anti-tnfrsf25 antibodies
CN108690136B (en) * 2017-04-05 2022-09-20 凯惠科技发展(上海)有限公司 Humanized anti-TPBG antibody, preparation method thereof, conjugate thereof and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (en) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Antitumor compositions containing taxane derivatives.
AU4441799A (en) * 1998-06-15 2000-01-05 Research Foundation Of The State University Of New York, The Monoclonal antibodies that recognize antigens associated with tumor metastasis
JP2003189851A (en) * 2001-12-28 2003-07-08 Japan Science & Technology Corp Human cd151 monoclonal-resistant antibody-producing hybridoma
JP2003321494A (en) * 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd Method for adjusting activation of prommp-7
US8318912B2 (en) * 2006-06-23 2012-11-27 Augmenta Biologicals, Llc Targeted immune conjugate comprising an antibody to glycophorin A and a M2e peptide
FR2907341B1 (en) * 2006-10-18 2012-08-17 Pf Medicament USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER
FR2929946B1 (en) * 2008-04-11 2010-05-28 Pf Medicament NOVEL ANTI-CD151 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
PL2079482T3 (en) 2011-07-29
MX2009003039A (en) 2009-04-02
WO2008049990A3 (en) 2008-09-12
JP5723420B2 (en) 2015-05-27
FR2907341A1 (en) 2008-04-25
CA2665912C (en) 2014-12-09
EP2079482B1 (en) 2011-02-23
ATE499387T1 (en) 2011-03-15
CA2665912A1 (en) 2008-05-02
RU2464041C2 (en) 2012-10-20
PT2079482E (en) 2011-05-25
TN2009000144A1 (en) 2010-10-18
US20120219569A1 (en) 2012-08-30
MA30777B1 (en) 2009-10-01
BRPI0717455A2 (en) 2013-12-24
JP2013253084A (en) 2013-12-19
IL198043A (en) 2015-03-31
ES2361696T3 (en) 2011-06-21
AU2007310763A1 (en) 2008-05-02
RS51729B (en) 2011-10-31
KR20090067219A (en) 2009-06-24
CN101528256B (en) 2013-10-02
AU2007310763B2 (en) 2011-02-17
KR101521863B1 (en) 2015-05-20
RU2009118440A (en) 2010-11-27
JP2010506888A (en) 2010-03-04
NO20091919L (en) 2009-05-18
HRP20110374T1 (en) 2011-06-30
HK1132904A1 (en) 2010-03-12
JP5757646B2 (en) 2015-07-29
CN101528256A (en) 2009-09-09
UA99601C2 (en) 2012-09-10
NZ575781A (en) 2012-06-29
IL198043A0 (en) 2011-08-01
FR2907341B1 (en) 2012-08-17
EP2079482A2 (en) 2009-07-22
US20090324600A1 (en) 2009-12-31
US8178096B2 (en) 2012-05-15
DK2079482T3 (en) 2011-06-14
SI2079482T1 (en) 2011-07-29
WO2008049990A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
DE602007012743D1 (en) USE OF AN ANTIBODY AGAINST CD151 IN THE TREATMENT OF PRIMARY CANCER
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
NO20085422L (en) Binding proteins for hepatocyte growth factor (HGF)
NO20085421L (en) Binding proteins for hepatocyte growth factor (HGF)
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
CL2008000020A1 (en) Compounds derived from substituted 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and malignant tumors.
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
EA200900819A1 (en) QUINAZOLINS FOR INHIBITION OF PDK1
NO20091661L (en) Use of pegylated IL-10 to treat cancer
UA108193C2 (en) APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
MX2009005597A (en) Compounds.
EP3103476A3 (en) Antibodies against a proliferating inducing ligand (april)
EA201070636A1 (en) INHIBITION OF THE PROTECTOR PROTEIN, STIMULATING MACROPHAGE (RON), AND METHODS OF ITS TREATMENT
ATE432281T1 (en) PYRROLOTRIAZINE KINASE INHIBITORS
UA99602C2 (en) Antibody that specifically binds to jam-a, capable of inhibiting the proliferation of tumor cells
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
EA200801425A1 (en) DIAZEPINONY
DE602005025459D1 (en) EPHB4-Binding Antibodies for the Inhibition of Angiogenesis and Tumor Growth
DE602007009204D1 (en) CYCLOPEPTIDE DERIVED FROM COLLAGEN TYPE IV WITH ANTIBODY EFFICACY
ATE541861T1 (en) USE OF AN ANTIBODY TO CD151 FOR EARLY TREATMENT OF CANCER
UA107655C2 (en) SELECTIVE BCL-2 ANTIAPOPTIC PROTEIN INHIBITORS FOR TREATMENT OF CANCER AND IMMUNE DISEASES
EA202090198A1 (en) COMBINED TREATMENT OF TUMORS EXPRESSING CD38